$11.73 Billion Gene Therapy Markets – Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The Gene Therapy Market was estimated to be USD 6,659.93 million in 2020 and is poised to grow at a CAGR of 28.32% by 2026 to reach USD 11,739.75 million.

The COVID-19 pandemic is expected to have a positive effect on the gene therapy market. Gene and cell therapy technology is expected to be used extensively in the development of vaccines used to treat COVID-19. For example, in January 2021, vaccine candidates developed by Mass General Brigham and made by utilizing gene-therapy technology elicited strong immune responses in animal models for the treatment of COVID-19.

The vaccine candidate was named AAVCOVID and the researchers received a USD 2.1 million grant to further develop the technology from the Bill & Melinda Gates Foundation. The vaccine which is being developed is likely to be far more convenient than the ones being sold in the market currently, as it has single-dose and can be stored at room temperature.

Different approaches are being used by other researchers, like those from the University of Pennsylvania. In collaboration with Regeneron, the researchers are using adeno-associated viral vectors to transport lab-made antibodies into the body. These developments are expected to affect market growth in a positive manner.

The factors that drive market growth include technological advancements, rising investments in R&D, and the growing prevalence of target diseases.

Gene therapies are developed for the treatment of diseases by modifying genetic information, which includes inactivating genes that function improperly or replacing a gene, which causes disease with a healthy copy of the gene. Gene therapy is being used to treat several diseases and has shown promising results.

Diseases such as Cystic Fibrosis, Cancer, Heart diseases, Diabetes, AIDS, Hemophilia can be cured by this method of treatment. Gene therapy is usually used to correct the defective gene to cure a specific disease or helps the body better fight against the diseases. There has been an increasing prevalence of many target diseases, such as cancer, rheumatoid arthritis, diabetes, Parkinson's disease, Alzheimer's disease, etc. that have been cured by several gene therapies present already in the market.

There has also been an increase in several genetic and numerous life-threatening disorders, especially heart diseases, AIDS, cystic fibrosis, and age-related disorders. Although gene therapy was initially targeted for inherited diseases, it is now used in the treatment of a variety of acquired problems including cancer and HIV. Initially delivered through viruses, now there are safer direct or biochemical vectors, while in the future nano-particles might deliver the drug of choice directly to the nucleus of affected cells.

For instance, according to the World Health Organization, an estimated 17.9 million people die due to cardiovascular diseases worldwide, each year. This represents 35% of global deaths. As gene therapy provides a complete cure to patients affected with genetic and other life-threatening disorders, rather than ease symptoms that happen with other treatments, it is becoming more popular.

Investment in research and development activities is also expected to have a significant effect on the market. Companies such as Pfizer Inc., are aiming to build a gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, expansion of R&D activities, as well as potential licensing and M&A activities.

Competitive Landscape

The global Gene Therapy market is highly competitive and consists of a few major players. Companies like Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., among others, hold the substantial market share in the Gene Therapy market.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Investments in the R&D

4.2.2 Technological Advancements

4.2.3 Growing Prevalence of Target Diseases like Cancer

4.3 Market Restraints

4.3.1 Lack of Standard Regulations

4.3.2 High Price of Products

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Indication

5.1.1 Cancer

5.1.2 Metabolic Disorders

5.1.3 Eye Disorders

5.1.4 Spinal Muscular Atrophy

5.1.5 Other Indications

5.2 By Technology

5.2.1 Adeno Virus Vector

5.2.2 Adeno-associated Virus Vector

5.2.3 Lentiviral Vector

5.2.4 Retroviral Vector

5.2.5 Herpes Virus Vector

5.2.6 Others

5.3 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Amgen Inc.

6.1.2 Biogen Inc.

6.1.3 Bluebird Bio Inc.

6.1.4 Gilead Sciences, Inc. (Kite Pharma)

6.1.5 Novartis AG

6.1.6 Orchard Therapeutics

6.1.7 Sibiono GeneTech Co. Ltd.

6.1.8 Spark Therapeutics (Roche)

6.1.9 UniQure N.V.

6.1.10 Abeona Therapeutics

6.1.11 Generation Bio

6.1.12 Poseida Therapeutics

6.1.13 Astellas Pharma

6.1.14 Voyager Therapeutics

6.1.15 Elevate Bio

6.1.16 Editas Medicine

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/j0vxpt

Read more:
$11.73 Billion Gene Therapy Markets - Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026 - ResearchAndMarkets.com - Business Wire